EuroMRD NGS ALL 2025

EuroMRD NGS ALL EQA scheme 2025

Task 9 (Pilot): IG/TR NGS based MRD quantification

Next-generation sequencing (NGS) using IG/TR rearrangements as targets is an optional new methodology to quantify minimal residual disease (MRD) in lymphoid malignancies. Recently, the EuroClonality-NGS Working Group published IG/TR NGS assays and the respective bioinformatics evaluation, for which a regular EQA scheme within the EuroMRD network is currently under development. In this pilot phase, rules for performance of these tasks are not finalized, so there is also no standard operating procedure.

Performance evaluation and report

Certificates of participation will be distributed after the EuroMRD meeting of the same calendar year.

EQA Educational meeting

During the ESLHO week in November, the annual EuroMRD meeting is organized. At this meeting, the results of all EuroMRD EQA schemes are shown (anonymized) and discussed with all EuroMRD participants, in small discussion groups as well as during plenary sessions.

Registration and participation fee

The EuroMRD NGS ALL EQA scheme is only available for participants of the EuroMRD Consortium. The participation fee is € 250. In addition, the EuroMRD annual fee is charged once to every EuroMRD participant.

Organization

The NGS ALL EQA scheme is organized by ESLHO (EQA Program Coordinator: Prof. Dr. Jacques J.M. van Dongen) in collaboration with the EuroMRD EQA Committee (NGS ALL scheme lead: Dr. Eva Froňková). The members of the EuroMRD EQA Committee are participants of the EuroMRD Consortium. The EuroMRD subject-matter experts provide support for:

• Pre-round: Case selection, determination of consensus results

• Post-round: Data analysis, performance evaluation, reporting

Details on the task division can be found below.

Task division